^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Pancreatic Cancer
    Drug:Dupert (fulzerasib) (KRAS G12C inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Innovent Biologics Press Release
    Title:

    Innovent Presents Clinical Data of Phase Ia Study for IBI351 (KRASG12C Inhibitor) as Monotherapy for Solid Tumors at the 2022 Chinese Society of Clinical Oncology (CSCO) Annual Meeting

    Published date:
    11/15/2022
    Excerpt:
    Favorable safety and tolerability and promising antitumor activity of IBI351 monotherapy were observed in previously-treated advanced NSCLC, CRC and pancreatic cancer harboring KRASG12C mutation.
    Trial ID:
    NCT05005234